EUVIMEDEUVIMED entdecken
Crossref

The role of [⁶⁸Ga]Ga-FAP-2286 PET/CT in the evaluation of treatment response in gastrointestinal system malignancies

Nalan Alan Selcuk iD, Gamze Beydagi iD, Kaan Akcay iD, Ayşegul Gormez iD, Turkay Toklu iD, Levent Kabasakal iD

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-025-07597-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Nalan Alan Selcuk und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Faculty of Medicine, Yeditepe University, Istanbul, Turkey. nalanselcuk@yahoo.com. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Gastrointestinal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study aimed to investigate the potential efficacy of [⁶⁸Ga]Ga-FAP-2286 PET/CT in evaluating treatment response in patients with gastrointestinal system malignancies. MATERIALS AND METHODS: Patients with histopathologically confirmed gastrointestinal malignancies who underwent [⁶⁸Ga]Ga-FAP-2286 PET/CT for treatment response assessment between November 2020 and January 2025 were included. All images were evaluated by three experienced nuclear medicine physicians. The maximum standardized uptake values (SUVmax), total tumor volumes, and total lesion FAP expression values of primary tumors and metastases were recorded. At the same time, serum tumor marker levels were analyzed. Imaging responses were assessed separately according to PERCIST criteria on [⁶⁸Ga]Ga-FAP-2286 PET/CT and RECIST criteria on CT. Survival outcomes were analyzed using the Kaplan-Meier method, and their association with treatment response on [⁶⁸Ga]Ga-FAP-2286 PET/CT was assessed using the Log-Rank (Mantel-Cox) test and Cox proportional hazards regression. A p-value < 0.05 was considered statistically significant in all analyses. RESULTS: A total of 100 [⁶⁸Ga]Ga-FAP-2286 PET/CT scans were performed in 50 patients (mean age: 61.62 ± 12.95), both before and after treatment. Among the included patients, 70% had gastric cancer, 14% had colon cancer, 8% had pancreatic cancer, 4% had appendiceal cancer, 2% had hepatocellular carcinoma (HCC), and 2% had cholangiocellular carcinoma. Primary/recurrent tumor lesions were observed in 62% of patients, lymph node metastases in 24%, visceral metastases in 10%, peritoneal metastases in 76%, and bone metastases in 14%. A strong correlation was found between tumor volumes and total lesion FAP expression measured by [⁶⁸Ga]Ga-FAP-2286 PET/CT and the corresponding serum tumor markers (Area Under the Curve [AUC] for delta tumor volume and total lesion FAP expression = 0.875). There was a statistically significant and near-perfect concordance between [⁶⁸Ga]Ga-FAP-2286 PET PERCIST and CT RECIST criteria (Kappa = 0.833, p < 0.05). Moderate agreement was found for primary tumors (Kappa = 0.526, p < 0.05) and bone metastases (Kappa = 0.657, p < 0.05), while excellent agreement was observed for lymph node (Kappa = 1.0, p < 0.05), peritoneal (Kappa = 0.815, p < 0.05), and visceral metastases (Kappa = 1.0, p < 0.05). According to the Kaplan-Meier analysis, treatment response assessed by [⁶⁸Ga]Ga-FAP-2286 PET/CT was predictive of overall survival (p = 0.02). Median overall survival was 7.6 months in patients with progressive disease and 19.8 months in those with stable disease, as defined by PERCIST criteria. Median survival was not reached in patients showing partial or complete response. CONCLUSION: In gastrointestinal system malignancies, a strong correlation was observed between serum tumor markers and both total tumor volumes and total lesion FAP expression values derived from [⁶⁸Ga]Ga-FAP-2286 PET imaging. Additionally, molecular response assessed by [⁶⁸Ga]Ga-FAP-2286 PET/CT was predictive of overall survival. [⁶⁸Ga]Ga-FAP-2286 PET/CT appears to be an effective tool for assessing treatment response and monitoring patients with gastrointestinal malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyGastrointestinal NeoplasmsHumansMaleFemaleMiddle AgedAgedGallium RadioisotopesTreatment OutcomeAdultAged, 80 and overQuinolines

Stichwörter der Autor:innen

FAP-2286 PET/CTGastrointestinal system malignanciesResponse evaluation

Substanzen

Gallium Radioisotopes68Ga-FAPIQuinolines

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Faculty of Medicine, Yeditepe University, Istanbul, Turkey. nalanselcuk@yahoo.com.
  • Department of Nuclear Medicine, Faculty of Medicine, Yeditepe University, Istanbul, Turkey.
  • Department of Radiology, Faculty of Medicine, Yeditepe University, Istanbul, Turkey.
  • Department of Nuclear Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.

ORCID-Profile: Nalan Alan Selcuk, Gamze Beydagi, Kaan Akcay, Ayşegul Gormez, Turkay Toklu, Levent Kabasakal

Zitieren

APA

Selcuk, N. A., Beydagi, G., Akcay, K., Gormez, A., Toklu, T., & Kabasakal, L. (2026). The role of [⁶⁸Ga]Ga-FAP-2286 PET/CT in the evaluation of treatment response in gastrointestinal system malignancies. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07597-1

Vancouver

Selcuk NA, Beydagi G, Akcay K, Gormez A, Toklu T, Kabasakal L. The role of [⁶⁸Ga]Ga-FAP-2286 PET/CT in the evaluation of treatment response in gastrointestinal system malignancies. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07597-1

BibTeX
@article{Selcuk2026,
  author = {Selcuk, Nalan Alan and Beydagi, Gamze and Akcay, Kaan and Gormez, Ayşegul and Toklu, Turkay and Kabasakal, Levent},
  title = {The role of [⁶⁸Ga]Ga-FAP-2286 PET/CT in the evaluation of treatment response in gastrointestinal system malignancies},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-025-07597-1}
}
Kostenlos starten →